By Arasu Kannagi Basil (Reuters) -Drug developer Maze Therapeutics said on Monday it was targeting a valuation of up to $728.1 million in its New York initial public offering, set to be the first U.S.

From securing a first home to navigating life’s challenges, Mark Goode and his team offer personalized mortgage solutions.

Ready to spend hours browsing for rare finds? These 8 massive flea markets in Oklahoma are filled with endless treasures ...